Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.
International journal of cancer, 2006-03, Vol.118 (5), p.1241-1247 Porter, Sarah Span, Paul N. Sweep, Fred C.G.J. Tjan‐Heijnen, Vivianne C.G. Pennington, Caroline J. Pedersen, Tanja X. Johnsen, Morten Lund, Leif R. Rømer, John Edwards, Dylan R. 2006
Details Autor(en) / Beteiligte Porter, Sarah Span, Paul N. Sweep, Fred C.G.J. Tjan‐Heijnen, Vivianne C.G. Pennington, Caroline J. Pedersen, Tanja X. Johnsen, Morten Lund, Leif R. Rømer, John Edwards, Dylan R. Titel ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma Ist Teil von International journal of cancer, 2006-03, Vol.118 (5), p.1241-1247 Ort / Verlag Hoboken: Wiley Subscription Services, Inc., A Wiley Company Erscheinungsjahr 2006 Quelle Free E-Journal (出版社公開部分のみ) Beschreibungen/Notizen We recently undertook expression profiling of all 19 human ADAMTS metalloproteinases (a disintegrin and metalloproteinase with thrombospondin motifs) in malignant and non‐neoplastic breast tissue and showed that 11 of the ADAMTS genes are dysregulated in breast carcinoma. We identified a subgroup of ADAMTSs, based on functional and amino acid sequence similarity (ADAMTS1, 4, 5, 8 and 15), to be the focus of further study in breast carcinoma. Further RNA expression analysis by real‐time PCR on a different cohort of 229 patients with breast cancer has identified ADAMTS8 as a predictor of poor overall survival (OS) (hazard ratio (HR) = 2.20, 95% C.I. = 1.29–3.74, p = 0.004) and confirmed ADAMTS15 as a predictor of prolonged relapse‐free survival (RFS) (HR = 0.54, 95% C.I. = 0.32–0.89, p = 0.016). We explored the differences in survival of the 4 groups that could be categorized based on the expression levels of ADAMTS8 and ADAMTS15. For both RFS and OS, the group with high ADAMTS8 and low ADAMTS15 expression had a particularly poor prognosis. This group had a 3‐fold higher chance of recurrence (HR = 3.03, 95% C.I. = 1.49–6.15, p = 0.001) and a greater than 5‐fold higher chance of death (HR = 5.40, 95% C.I. = 2.16–13.5, p < 0.001) than the most favorable prognostic group. This prediction of poor prognosis by ADAMTS8 and ADAMTS15 expression was found to be independent of other classical clinicopathological factors. Results observed in FVB‐PyMT mice, a robust transgenic model of highly metastatic breast carcinoma, fitted the expectation that relatively high expression levels of ADAMTS8 together with low expression levels of ADAMTS15 seen in human breast carcinoma are associated with a poor clinical outcome. In summary, ADAMTS8 and ADAMTS15 have emerged as novel predictors of survival in patients with breast carcinoma. © 2005 Wiley‐Liss, Inc. Sprache Englisch Identifikatoren ISSN: 0020-7136
eISSN: 1097-0215
DOI: 10.1002/ijc.21476
Titel-ID: cdi_proquest_miscellaneous_67591494
Format – Schlagworte ADAM Proteins - genetics , ADAM Proteins - metabolism , ADAMTS , ADAMTS Proteins , Adult , Aged , Aged, 80 and over , Biological and medical sciences , breast carcinoma , Breast Neoplasms - diagnosis , Breast Neoplasms - genetics , Breast Neoplasms - metabolism , Breast Neoplasms - pathology , Gene Expression Regulation, Neoplastic , Gynecology. Andrology. Obstetrics , Humans , Mammary gland diseases , Medical sciences , metalloproteinase , Middle Aged , Prognosis , Survival Rate , Tumors Weiterführende Literatur Empfehlungen zum selben Thema automatisch vorgeschlagen von bX